Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin

Clinical and Experimental Medicine

Volumn 5, Issue 4, 2005, Pages 135-140

  Ephrem, A ^a   Misra, N ^a   Hassan, G ^a   Dasgupta, S ^a   Delignat, S ^a   Duong Van Huyen, J P ^a   Chamat, S ^a   Prost, F ^a   Lacroix Desmazes, S ^a   Kavery, S V ^a   Kazatchkine, M D ^a  

^a INSERM   (France)

Author keywords

Autoimmune disorders; Inflammatory diseases; Intravenous immunoglobulin; Mechanisms

Indexed keywords

AUTOANTIBODY; COMPLEMENT; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; PRIORITY JOURNAL; PROTEIN INDUCTION; RECEPTOR BLOCKING; REGULATORY MECHANISM; REMYELINIZATION; REVIEW; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; MYELIN SHEATH; NEUTRALIZATION TESTS; T-LYMPHOCYTES;

EID: 29144523502     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-005-0079-y     Document Type: Review

References (51)

1. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747-755
2. Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367-2375
3. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV (2004) Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 25:306-310
4. Dwyer JM (1992) Manipulating the immune system with immune globulin. N Engl J Med 326:107-116
5. Gelfand E, Landwehr L, Esterl B, Mazer B (1996) Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 104:61-66
6. Dalakas MC (1997) Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 126:721-730
7. Yu Z, Lennon V (1999) Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340:227-228
8. Lemieux R, Bazin R, Neron S (2005) Therapeutic intravenous immunoglobulins. Mol Immunol 42:839-848
9. Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J (1993) Immunologically active proteins in intravenous immunoglobulin. Lancet 342:678
10. Blasczyk R, Westhoff U, Grossewilde H (1993) Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341:789-790
11. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B (2001) High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345:1870-1876
12. Ballow M (1997) Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 100:151-157
13. Van Schaik IN, Lundkvist I, Vermeulen M, Brand A (1992) Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 12:325-334
14. Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104:10-20
15. Vuist W, Van Schaik I, Van Lint M, Brand A (1997) The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Immunol 17:301-310
16. Modiano JF, Amran D, Lack G, Bradley K, Ball C, Domenico J, Gelfand EW (1997) Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin. Clin Immunol Immunopathol 83:77-85
17. Sewell WA, Jolles S (2002) Immunomodulatory action of intravenous immunoglobulin. Immunology 107:387-393
18. Misra N, Bayry J, Ephrem A, Dasgupta S, Delignat S, Van Huyen JP, Prost F, Lacroix-Desmazes S, Nicoletti A, Kazatchkine MD, Kaveri SV (2005) Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol 252[Suppl 1]:I1-I6
19. Kazatchkine MD, Dietrich G, Hurez V, Ronda N, Bellon B, Rossi F, Kaveri SV (1994) V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 139:79-107
20. Andersson U, Bjork E, Skansen-Saphir U, Andersson J (1994) Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 139:21-42
21. Andersson UG, Bjork L, Skansén-Saphir U, Andersson JP (1993) Down-regulation of cytokine production and IL-2 receptor expression by pooled human IgG. Immunology 79:211-216
22. Ruiz de Souza V, Carreno MP, Kaveri SV, Ledur A, Sadeghi H, Cavaillon JM, Kazatchkine MD, Haeffner-Cavaillon N (1995) Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal poly-specific IgG (intravenous immunoglobulin). Eur J Immunol 25:1267-1273
23. Sharief M, Ingram D, Swash M, Thompson E (1999) Ev. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 52:1833-1838
24. Mouzaki A, Theodoropoulou M, Gianakopoulos I, Vlaha V, Kyrtsonis MC, Maniatis A (2002) Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 100:1774-1779
25. Basta M, Fries EF, Frank MM (1991) High-dose intravenous immunoglobulin inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77:376-380
26. Lutz HU, Stammler P, Bianchi V, Trueb RM, Hunziker T, Burger R, Jelezarova E, Spath PJ (2004) Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103:465-472
27. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, Szebeni J, Alving CR, Carroll MC, Berkower I, Stojilkovic SS, Metcalfe DD (2003) F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9:431-438
28. Mollnes TE, Hogasen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, Perricone R (1998) High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 48:312-317
29. Basta M, Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complements fragments. J Clin Invest 94:1729-1735
30. Dalakas MC (1998) Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51:S2-S8
31. Samuelsson A, Towers T, Ravetch J (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484-486
32. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18:573-581
33. Crow AR, Song S, Freedman J, Helgason CD, Humphries RK, Siminovitch KA, Lazarus AH (2003) IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102:558-560
34. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schlutter SF, Yocum DE, Edmundson AB (1992) Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proc Natl Acad Sci USA 89:3325-3329
35. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, Bendtzen K (1998) Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in Human IgG preparations. Blood 91:2054-2061
36. Bendtzen K, Hansen MB, Ross C, Svenson M (1998) High-avidity autoantibodies to cytokines. Immunol Today 19:209-211
37. Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, Kaveri SV (2003) Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48:3497-3502
38. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD (1993) Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 92:369-372
39. Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, Kazatchkine MD (1994) Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (Intravenous immunoglobulin, IVIg). Therap Immunol 1:269-278
40. Kaveri S, Vassilev T, Hurez V Lengagne R, Cot S, Pouletty P, Glotz D, Kazatchkine M (1996) Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg). J Clin Invest 97:865-869
41. Vassilev T, Kazatchkine MD, Duong Van Huyen JP, Mekrache M, Bonnin E, Korinth D, Baruch D, Mani JC, Lecroubier C, Schriever F, Kaveri SV (1999) Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (Intravenous Immunoglobulin, IVIg). Blood 93:3624-3631
42. Prasad N, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV (1998) Therapeutic preparations of normal polyspecific immunoglobulin G (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161:3781-3790
43. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490-493
44. Sooryanarayana, Prasad N, Bonnin E, Pashov A, Ben Jilani K, Ameisen JC, Kazatchkine MD, Kaveri SV (1999) Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G. Biochem Biophys Res Commun 264:896-901
45. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y, Delignat S, Varambally S, Oksenhendler E, Levy Y, Debre M, Kazatchkine MD, Hermine O, Kaveri SV (2004) Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 101:14210-14215
46. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevallier A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758-765
47. Raju R, Dalakas MC (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128:1887-1896
48. van Engelen BG, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M (1994) Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry 57[Suppl]:65-68
49. Warrington AE, Asakura K, Bieber AJ, Ciric B, Van Keulen V Kaveri SV, Kyle RA, Pease LR, Rodriguez M (2000) Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci USA 97:6820-6825
50. Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH (2002) Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 125:1875-1886
51. Sorensen PS (2003) The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci 206:123-130